Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
8/10/2007
1.
Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
16 to physiologic 70
NCI
CLB-8642
CALGB-8642
Last Modified:
8/1/1991
2.
Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Advanced Ovarian Carcinoma (Summary Last Modified 08/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 75
EORTC-16902O
Last Modified:
7/1/1991
3.
Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Breast Cancer (Summary Last Modified 07/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 75
EORTC-16902B
Last Modified:
7/1/1991
4.
Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Colorectal Cancer (Summary Last Modified 07/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 75
EORTC-16902C
Last Modified:
7/1/1991
5.
Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic non-Small Cell Lung Cancer (Summary Last Modified 07/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 75
EORTC-16902L
Last Modified:
10/1/1992
6.
Phase II Study of Elsamitrucin in Patients with Unresectable or Metastatic Nonsmall Cell Lung Cancer (Summary Last Modified 10/92)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 to 75
CAN-NCIC-IND65
NCI-V92-0107, IND65
7.
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
ELSA 2004-001
NCT00090090
8.
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Other
13NHL-04-1
NCT00184080
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute